Login to Your Account



Kindex brewing diabetes drug with hops-derived humulone; $5M series A

By Randy Osborne
Staff Writer

Tuesday, March 25, 2014
It’s only $5 million in series A funding, but enough to move start-up Kindex Pharmaceuticals Inc. into a phase II trial with lead compound KDT 501, a hops-derived candidate for type 2 diabetes that regulates the cross-talk between macrophages and adipocytes to influence the complex of proteins that regulate inflammation, also known as the inflammasome.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription